ATE546448T1 - Urotensin-ii-rezeptorantagonisten - Google Patents
Urotensin-ii-rezeptorantagonistenInfo
- Publication number
- ATE546448T1 ATE546448T1 AT09791047T AT09791047T ATE546448T1 AT E546448 T1 ATE546448 T1 AT E546448T1 AT 09791047 T AT09791047 T AT 09791047T AT 09791047 T AT09791047 T AT 09791047T AT E546448 T1 ATE546448 T1 AT E546448T1
- Authority
- AT
- Austria
- Prior art keywords
- urotensin
- receptor antagonists
- compounds
- formula
- prodrugs
- Prior art date
Links
- 102000012327 Urotensin II receptors Human genes 0.000 title abstract 2
- 108050002984 Urotensin II receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13763408P | 2008-08-02 | 2008-08-02 | |
| PCT/US2009/052403 WO2010017105A1 (en) | 2008-08-02 | 2009-07-31 | Urotensin ii receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE546448T1 true ATE546448T1 (de) | 2012-03-15 |
Family
ID=41259404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09791047T ATE546448T1 (de) | 2008-08-02 | 2009-07-31 | Urotensin-ii-rezeptorantagonisten |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9079896B2 (de) |
| EP (1) | EP2326644B1 (de) |
| JP (1) | JP2011529966A (de) |
| AT (1) | ATE546448T1 (de) |
| CA (1) | CA2732762A1 (de) |
| ES (1) | ES2379762T3 (de) |
| WO (1) | WO2010017105A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759342B2 (en) | 2006-07-31 | 2014-06-24 | Janssen Pharmaceutica Nv | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists |
| TWI527818B (zh) * | 2011-03-15 | 2016-04-01 | 特留斯治療學有限公司 | 三環旋轉酶抑制劑 |
| TW201710257A (zh) | 2015-04-17 | 2017-03-16 | 艾伯維有限公司 | Tnf信號傳遞之三環調節劑 |
| TW201706258A (zh) | 2015-04-17 | 2017-02-16 | 艾伯維有限公司 | 作為tnf信號傳遞調節劑之吲唑酮 |
| WO2016168638A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3629266A (en) * | 1969-03-03 | 1971-12-21 | Miles Lab | (phenyl piperidino alkyl)3 4-dihydrocarbostyrils |
| US6546112B1 (en) * | 1993-11-18 | 2003-04-08 | Digimarc Corporation | Security document with steganographically-encoded authentication data |
| AU7449198A (en) | 1997-05-21 | 1998-12-11 | Japan Tobacco Inc. | Phthalimide derivatives and pharmaceutical containing said derivatives |
| AU7548298A (en) * | 1997-05-30 | 1998-12-30 | Meiji Seika Kaisha Ltd. | Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same |
| US6214857B1 (en) * | 1997-07-31 | 2001-04-10 | Celgene Corporation | Substituted alkanohydroxamic acids and method of reducing TNFα levels |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| DE19933611A1 (de) | 1999-07-17 | 2001-01-18 | Aventis Res & Tech Gmbh & Co | Verfahren zur Herstellung von Aminen durch homogen katalysierte reduktive Aminierung von Carbonylverbindungen |
| WO2001045711A1 (en) * | 1999-12-21 | 2001-06-28 | Smithkline Beecham Corporation | Urotensin-ii receptor antagonists |
| GB0027705D0 (en) * | 2000-11-11 | 2000-12-27 | S P A | Novel compounds |
| US20040039017A1 (en) | 2000-12-11 | 2004-02-26 | Dashyant Dhanak | Urotensin-II receptor antagonists |
| DE10138140A1 (de) | 2001-08-09 | 2003-02-20 | Degussa | Verfahren zur Herstellung von Aminen durch reduktive Aminierung von Carbonylverbindungen unter Transfer-Hydrierungsbedingungen |
| NZ533566A (en) | 2001-12-28 | 2007-03-30 | Acadia Pharm Inc | Tetrahydroquinoline analogues as muscarinic agonists |
| US6660736B2 (en) * | 2002-03-27 | 2003-12-09 | Hoffmann-La Roche Inc. | Phthalimido derivatives and a process for their preparation |
| GB0209244D0 (en) | 2002-04-23 | 2002-06-05 | Glaxo Group Ltd | Compounds |
| US20040077529A1 (en) | 2002-06-10 | 2004-04-22 | Per-Fredrik Lehmann | Urotensin II receptor agents |
| DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| AU2004218456A1 (en) | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists. |
| DE602004032522D1 (de) * | 2003-03-12 | 2011-06-16 | Celgene Corp | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung |
| ZA200507284B (en) | 2003-03-12 | 2007-03-28 | Celgene Corp | 7-amino-isoindolyl compounds and their pharmaceutical uses |
| TW200900399A (en) * | 2003-10-01 | 2009-01-01 | Speedel Experimenta Ag | Organic compounds |
| WO2005034873A2 (en) | 2003-10-09 | 2005-04-21 | Smithkline Beecham Corporation | A method for reducing anti-neoplastic agent induced side-effects |
| CA2548447A1 (en) * | 2003-12-08 | 2005-06-23 | Warner-Lambert Company Llc | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia |
| WO2005072226A2 (en) | 2004-01-19 | 2005-08-11 | Smithkline Beecham Corporation | Use of urotensin-ii receptor antagonists in the treatment of inflammatory bowel diseases |
| BRPI0510166A (pt) * | 2004-04-23 | 2007-10-02 | Celgene Corp | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| CN102295636A (zh) * | 2005-07-29 | 2011-12-28 | 弗·哈夫曼-拉罗切有限公司 | 吲哚-3-基-羰基-哌啶和哌嗪衍生物 |
| TW200804347A (en) * | 2006-01-10 | 2008-01-16 | Janssen Pharmaceutica Nv | Urotensin II receptor antagonists |
| US8759342B2 (en) * | 2006-07-31 | 2014-06-24 | Janssen Pharmaceutica Nv | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists |
| PA8782701A1 (es) * | 2007-06-07 | 2009-01-23 | Janssen Pharmaceutica Nv | Antagonistas del receptor de urotensina ii |
-
2009
- 2009-07-31 US US12/533,257 patent/US9079896B2/en not_active Expired - Fee Related
- 2009-07-31 JP JP2011522131A patent/JP2011529966A/ja not_active Ceased
- 2009-07-31 EP EP09791047A patent/EP2326644B1/de not_active Not-in-force
- 2009-07-31 AT AT09791047T patent/ATE546448T1/de active
- 2009-07-31 ES ES09791047T patent/ES2379762T3/es active Active
- 2009-07-31 WO PCT/US2009/052403 patent/WO2010017105A1/en not_active Ceased
- 2009-07-31 CA CA2732762A patent/CA2732762A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010017105A1 (en) | 2010-02-11 |
| CA2732762A1 (en) | 2010-02-11 |
| US9079896B2 (en) | 2015-07-14 |
| EP2326644A1 (de) | 2011-06-01 |
| US20100029616A1 (en) | 2010-02-04 |
| EP2326644B1 (de) | 2012-02-22 |
| ES2379762T3 (es) | 2012-05-03 |
| JP2011529966A (ja) | 2011-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE542813T1 (de) | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren | |
| MX2011013884A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas. | |
| BRPI0910182B8 (pt) | composto de fórmula (i), composição farmacêutica e uso de um composto | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
| EA201100503A1 (ru) | Глюкозидные производные и их применения | |
| EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
| MY165113A (en) | Piperidinone carboxamide azaindane cgrp receptor antagonists | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
| BRPI1013821A8 (pt) | piridinas substituídas como antagonistas de ccr3. | |
| GEAP202213376A (en) | Inhibitors of influenza viruses replication | |
| EA201000113A1 (ru) | Пиразольные соединения | |
| EA201001724A1 (ru) | Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов | |
| MA34069B1 (fr) | Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a) | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| MX390264B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| EA201071329A1 (ru) | Диамидные производные адамантана и их применение | |
| IN2014CN04530A (de) | ||
| MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
| EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
| EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
| EA201170722A1 (ru) | Лактамы в качестве ингибиторов бета-секретазы | |
| EA201300034A1 (ru) | Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения |